Subscribe To
CPRX / New Strong Buy Stocks for October 11th
CPRX News
By GlobeNewsWire
October 23, 2023
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET The Company to Host a Conference Call and Webcast on November 9, more_horizontal
By Zacks Investment Research
October 18, 2023
3 Solid Stocks to Buy for Superb Earnings Acceleration
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration. more_horizontal
By Zacks Investment Research
October 16, 2023
Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse
The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton more_horizontal
By Zacks Investment Research
October 12, 2023
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank. more_horizontal
By Zacks Investment Research
October 11, 2023
New Strong Buy Stocks for October 11th
PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023. more_horizontal
By Zacks Investment Research
October 6, 2023
4 Stocks That Exhibit Solid Earnings Acceleration
Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings accelerati more_horizontal
By GlobeNewsWire
September 18, 2023
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutica more_horizontal
By Zacks Investment Research
September 8, 2023
Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? more_horizontal